CSTL

Castle Biosciences is a molecular-diagnostics company whose story turned in FY2025: after three years of 46-61% revenue growth (FY2021 $94M → FY2024 $332M), the top line stalled to +3.7% ($344M), and GAAP profitability reversed from FY2024's +$18.2M net income back to a -$24.2M loss, with operating income at -$42.8M (-12.4% margin) and diluted EPS of -$0.83. That deceleration is the whole ballgame — for a company priced on growth, a jump from ~50% to low-single-digit revenue growth is a fundamental change, and it likely reflects maturation/reimbursement dynamics in the core DecisionDx-Melanoma and TissueCypher franchises the MD&A calls out as the revenue base. Note the provided gross-profit figure is stale (FY2020, $53M), so the 15.4% 'gross margin' is a data artifact, not the current lab economics — treat FY2025 gross margin as unavailable.

What keeps this a hold rather than a sell is the balance sheet and cash engine. Liabilities/equity is just 0.23x, long-term debt is a token $9.64M against $471M of equity and $117M of cash, and current assets ($361M) cover current liabilities ($68.7M) more than five times over. Crucially, despite the GAAP loss the business generated +$64.3M of operating cash flow; the net loss is heavily driven by D&A, which spiked +154.9% to $40.8M, alongside $36M of capex (new Friendswood HQ and expanded Phoenix/Pittsburgh/Scottsdale lab space per Item 2). This is a self-funding, non-distressed company, not a cash-burn story — the -5.1% ROE and -$224M accumulated deficit reflect a historically pre-profit diagnostics build-out, not imminent stress.